Mulvihill Premium Yield Fund Declares Monthly Fund Distribution for Its ETF Class
TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- (TSX: MPY) Mulvihill Premium Yield Fund has declared a monthly cash distribution for its ETF Class in the amount of $0.04667 per unit, payable on September 7, 2023 to unitholders of record on August 31, 2023.
For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at [email protected] or visit www.mulvihill.com.
John Germain, Senior Vice-President & CFO
Mulvihill Capital Management Inc. 121 King Street West Suite 2600 Toronto, Ontario, M5H 3T9
Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.
Connexus, the nation's leading procurement and request for proposal (RFP) platform in the real estate sector, announced today Heather Moore as President and Chief Operating Officer (COO), signifying a strategic move by the Company to enhance its...
CryoMass Technologies Inc. (the "Company" or "CryoMass") , a pioneering leader in cryogenic systems for refinement of trichome-rich crops, today announced the sale of its first production model. As previously announced in January of this year,...
Fair360, formerly DiversityInc, has named Toyota North America* one of its 2024 Top 50 Companies, ranking fourth among the 160 companies participating in the survey. Toyota has maintained its position for the third year in a row and continues to be...
Fiera Capital Corporation ("Fiera Capital" or the "Company"), a leading independent asset manager with over C$165.2 billion AUM as at 31 March 2024, is proud to announce that it has been selected to manage fixed income investments on behalf of...
In a groundbreaking collaboration between world-renowned three-Michelin-star Chef Corey Lee and Hyundai Motor Group Innovation Center Singapore (HMGICS), Na...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today its financial results and operational...
